VERIGRAFT AB, a leader in personalized tissue-engineered grafts, is excited to announce two grants from Sweden’s innovation agency, Vinnova. These funds will support groundbreaking projects in collaboration with two key partners: CCRM Nordic(Centre for Commercialization of Regenerative Medicine) and RISE(Research Institutes of Sweden).
The first project focuses on improving VERIGRAFT’s bioreactor technology, a critical part of the company’s GMP-compliant process for producing custom vascular grafts. Working with CCRM Nordic, VERIGRAFT will optimize its GMP (Good Manufacturing Practice) bioreactors to ensure high quality and scalability for clinical use.
The second project, in partnership with RISE, will use advanced 3D printing to create innovative scaffolds and develop a strong foundation for next-generation tissue-engineered products. This will help establish the technology needed to deliver tailored solutions in regenerative medicine.
“These Vinnova grants highlight the strength of our technology and our commitment to personalized medicine,“ says Petter Björquist, CEO of VERIGRAFT. “Through these collaborations, we’re addressing key manufacturing challenges and setting the stage for future breakthroughs in tissue engineering.”
These projects align with VERIGRAFT’s mission to transform treatment for patients with chronic vascular diseases and beyond. By combining expertise from CCRM Nordic and RISE, VERIGRAFT is advancing regenerative medicine to improve lives worldwide.